Bortezomib Before, During and After Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed AL Amyloidosis  by Huang, X.H. et al.
S60 Other Specific Nephropathieshttp://dx.doi.org/10.1016/j.hkjn.2015.09.0060046
Targeting c-fms Kinase Attenuates Aristolochic Acid Nephropathy in
Mice
X. Y. Dai1,2, X. R. Huang1, P. Fu3, L. Zhou3, C. Manthey4, D. J. Nikolic-
Paterson5, H. Y. Lan1
1Department of Medicine & Therapeutics, Li Ka Shing Institute of Health
Sciences, CUHK-Shenzhen Research Institute, The Chinese University of
Hong Kong, Hong Kong, China
2Division of Nephrology, Mianyang Central Hospital, Mianyang, Sichuan,
China
3Division of Nephrology, West China Hospital of Sichuan University,
Chengdu, Sichuan, China
4Janssen Research & Development, LLC, Radnor, PA, USA
5Department of Nephrology, Monash Health and Monash University
Department of Medicine, Clayton, Victoria, Australia
Background: Aristolochic acid nephropathy (AAN) is a progressive chronic
kidney disease related to the use of Chinese herbal medicine and is charac-
terized by extensive tubulointerstitial fibrosis and inflammation with macro-
phage infiltration. However, treatment of AAN remains ineffective. Thus,
the present study aimed to develop a new therapeutic strategy for chronic
AAN by targeting macrophages with a selective inhibitor of tyrosine kinase
activity of macrophage colony-stimulating factor receptor (fms-I).
Methods: Chronic AAN was induced in C57BL/6 mice by intraperitoneal in-
jection of aristolochic acid at a dose of 5 mg/kg every other day for 4 weeks.
fms-I in an optimal dose of 10 mg/kg twice daily (i.p) was given at the begin-
ning of induction of AAN or at the established AAN on day 14. The therapeu-
tic effect of fms-I on chronic AAN was examined at day 28.
Results: Treatment with fms-I largely suppressed F4/80+ macrophage and
CD3+ T cell infiltration and upregulation of proinflammatory cytokines (MIF,
TNFa, MCP-1), resulting in protection against acute and chronic AAN by
inhibiting 24-hour proteinuria, elevated levels of serum creatinine, upregu-
lation of KIM-1, and progressive renal fibrosis including accumulation of a-
SMA+ myofibroblasts and collagen I. Moreover, administration of fms-I to
the established AAN at day 14 also halted the disease progression of chronic
AAN at day 28. Further studies revealed that the therapeutic effect of fms-I
on chronic AAN was associated with blockade of both NF-kB and TGF-b/Smad
pathways.Conclusion: Macrophages play a pathogenic role in the development of
chronic AAN. Targeting macrophages with fms-I has therapeutic potential
for chronic AAN.http://dx.doi.org/10.1016/j.hkjn.2015.09.0070059
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Objective: Autosomal dominant polycystic kidney disease (ADPKD), an
inherited disease characterized by massive enlargement of fluid-filled cysts
in the kidney with an incidence rate of 1:1000e1:400, is a common cause of
renal failure. There is no effective therapy for ADPKD. Repulsive guidance
molecular b (RGMb), a co-receptor for bone morphogenetic protein
signaling and also a ligand for neogenin, is expressed at the epithelial cells
in kidney. RGMb has been reported to induce apoptosis in renal tubular
cells. The aim of this study was to determine if RGMb played a role in
ADPKD development.
Methods: MDCK cyst model, embryonic kidney cyst model and Pkd1flox/+;
Ksp-Cre PKD mouse model were used to assess the effect of RGMb in ADPKD.
Results: The experimental results showed that RGMb overexpression inhibited
MDCK cyst formation in 3D collagen matrix. Compared with control MDCK cells
whose cysts contained a single lumen with forskolin stimulation, RGMb-MDCK
cells sprawled into the colonies without cystic structure. A few of identifiable
cysts containedmultiple smaller lumensand thickerwalls. H&E staining showed
that RGMbnull kidneyshad interstitial hyperplasia anddecreased tubular struc-
tures, especially in theboundary area of renal cortex andmedulla. DBA staining
revealed less branched uretic bud in E13.5 RGMb null mouse embryonic kidney,
which suggested that deficiency of RGMbwould retard uretic budbranchingand
negatively modulate collecting duct development. Western blot analysis
exhibited increased phosphorylation of Smad1/5/8 in RGMb-MDCK cells, indi-
cating BMP-Smad1/5/8 pathway was important in ADPKD development.
Conclusion: Our data suggest that RGMb plays an important role in kidney
development and inhibits ADPKD by regulating BMP-Smad1/5/8 pathway.http://dx.doi.org/10.1016/j.hkjn.2015.09.0080061
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Objective: We demonstrated that the outcome of treating AL amyloidosis
with bortezomib-dexamethasone (BD) induction followed by autologous
hematopoietic stem cell transplantation (ASCT) was superior to the
outcome of the ASCT treatment alone previously. To further improve the
hematologic response rate, we conducted a prospective trial of bortezo-
mib before, in and after ASCT in patients with newly diagnosed AL
amyloidosis.
Methods: Newly diagnosed AL amyloidosis patients who met the criteria of
ASCT could be included. Treatment schedule consisted of two cycles of BD
induction therapy (bortezomib 1.3 mg/m2 and dexamethasone 40 mg/d on
days 1, 4, 8 and 11 followed by 10 days of rest), ASCT treatment (the condi-
tioning regimen consisted of melphalan and bortezomib, the dose of borte-
zomib was 1 mg/m2 on days 6, 3, +1, +4), and four additional 21-day
cycles of bortezomib treatment (with a dose of 1.6 mg/m2 on days 1 and 8
of the cycle) will be conducted as consolidation therapy after ASCT. Hema-
tologic response, tolerability and survival were observed.
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diac involvement. The overall hematologic response rate was 94.4% (17/
18), including 13 patients (72.2%) with complete response, 4 patients
(22.2%) with very good partial response. The organ response rate was
72.2%. The organ response was reached in 13 patients of the 18 patients
with renal involvement and 7 of the 9 patients with cardiac involvement.
Peripheral neuropathy and infection were the common adverse events,
and 4 patients have been discontinued bortezomib for neuropathy. No
death occurred. After a median follow up of 24 months, the overall survival
was 100%, and the estimated progression free survival was 91% at 48
months.
Conclusion: Our preliminary data suggest that incorporating bortezomib into
induction, conditioning and consolidation with ASCT yielded a high rate of
hematologic response with tolerable toxicity.
(ClinicalTrial.gov Identifier: NCT01273844)http://dx.doi.org/10.1016/j.hkjn.2015.09.0090062
C3 Glomerulonephritis Associated with Monoclonal Gammopathy
L. H. Zhang, Z. Chen, F. Xu, T. Zhang, H. T. Zhang, Y. C. Ge, Y. Zhou,
C. H. Zeng, W. X. Hu, Z. H. Liu, Z. Tang
National Clinical Research Center of Kidney Disease, Research Institute of0062
Table 1. Demographics and Laboratory Evaluation for Patients with Monoclona
Patient No. 1 2 3
Sex M M M
Age (y) 48 60 54
Duration of renal disease (m) 21 36 4
Hypertension Yes Yes Yes
Proteinuria (g/d) 1.0 3.0 4.5
Hematuria (104/ml) 30 3 36
Alb (g/l) 42.0 24.0 33.9
Glo (g/l) 22.7 17.8 24.9
SCr (mg/dl) 0.9 2.7 0.8
Hb (g/dL) 12.9 7.5 14.2
C3 (g/L) 1.0 0.6 0.4
C4 (g/L) 0.3 0.1 0.1
C3NeF Negative Negative Negat
AntiFH antibody Negative Negative Negat
Factor H Normal ND Norm
k:l Ratio 0.8 1.4 1.0
Immunofixation (serum) IgAl IgGl IgGk
Plasma cells in bone marrow ND Normal Norm
Alb Z albumin; SCr Z serum creatinine; Hb Z hemoglobin; M Z male; F Z fe
Reference ranges are as follows: proteinuria, 0.4 g/d; Alb, 35.0e55.0 g/L; SCr
0062
Table 2. Demographics and Laboratory Evaluation for Patients without Monoclo
Patient No. 1 2 3 4
Age (y) 77 27 41 56
Sex M F F M
Hypertension Yes No Yes Yes
Proteinuria (g/d) 2.4 0.9 4.3 1.6
Hematuria (104/ml) 75 17 75 76
Alb (g/l) 33.5 39.3 21.8 43.3
SCr (mg/dl) 1.9 0.5 0.7 0.7
Hb (g/dL) 9.9 12.3 11.5 12.8
C3 (g/L) 0.9 0.1 0.1 0.6
C4 (g/L) 0.2 0.1 0.1 0.2
C3NeF Negative Negative Negative Negative
AntiFH antibody Negative Negative Negative Negative
Factor H Normal Normal Normal Normal
Alb Z albumin; SCr Z serum creatinine; Hb Z hemoglobin; M Z male; F Z fe
Reference ranges are as follows: proteinuria, 0.4 g/d; Alb, 35e55 g/L; SCr, 0Nephrology, Jinling Hospital, Nanjing University School of Medicine,
Nanjing, Jiangsu, China
Background: C3 glomerulonephritis (GN) has been a recently introduced GN
resulting from dysregulation of the alternative pathway (AP) of complement.
Monoclonal gammopathy is an important secondary cause of dysregulation of
the AP, which has been a research hotspot at present.
Methods: Between March 2004 to April 2015, in a total of 16 patients with C3
GN, 7 patients had evidence of monoclonal immunoglobulin in serum. Clin-
ical features, hematologic findings, kidney biopsy, complement pathway ab-
normalities, treatment, and follow-up were collected.
Results: Patients with monoclonal immunoglobulin were 5 males and 2 fe-
males, 44e65 (mean, 55.4) years old. All of them had proteinuria ranging
from 1.04e7.34 g/d. Microscopic hematuria was observed in 6 patients,
elevated serum creatine (SCr) in 3 patients, hypertension in 6 patients, low
serum complement C3 in 4 patients, and complement C4 was normal in all pa-
tients (Table 1). No abnormalities were found for serum C3 nephritic factors
(C3NeFs), factor H and anti-factor H antibody. The most common monoclonal
gammopathy was IgGl (3 patients). Other gammopathies included IgGk (2 pa-
tients), IgAl (one patient), and light chain k (one patient). Elevated plasma
cells were observed in 2 of 6 patients (Table 1). Membranoproliferative GN
was present in all patients (Table 2). Two patients with abnormal plasma cells
received thalidomide plus dexamethasone, of whom one achieved long-time
complete remission in renal disease, and one had progression in kidney dis-
ease. The other 5 patients received either Tripterygium wilfordii and/or glu-
cocorticosteroid, of whom one was lost to follow-up, 4 had improvement in
urine analysis, and 3 had stable renal function (Table 3).l Gammopathy.
4 5 6 7
M M F F
65 44 64 53
42 67 3 60
No Yes Yes Yes
1.2 3.7 1.7 7.3
18 75 1000 78
35.5 24.6 30.0 21.4
19.9 17.9 47.0 23.2
0.9 0.7 2.4 1.7
5.9 15.5 6.0 8.4
0.8 0.9 0.6 0.4
0.2 0.2 0.1 0.1
ive Negative Negative Negative Negative
ive Negative Negative Negative Negative
al Normal Normal Normal Normal
1.5 1.9 0.2 3.5
IgGl LCk IgGl IgGk
al Normal 6.5% 45.5% Normal
male; ND Z none detected.
, 0.51e1.24 mg/dl; Hb, 12.0e17.5 g/dl; C3, 0.8e1.8 g/L; C4, 0.1e0.4 g/L.
nal Gammopathy.
5 6 7 8 9
70 39 42 13 19
M F F M F
Yes Yes Yes No No
4.0 2.0 0.9 0.6 1.0
256 11 2 250 3
28.1 37.1 35.9 45.3 45.8
1.8 0.9 0.8 0.6 0.6
6.4 13.5 12.5 12.7 13.2
1.5 0.7 0.8 0.5 0.7
0.3 0.2 0.2 0.1 0.1
Negative Negative Negative Negative Negative
Negative Negative Negative Negative Negative
Normal Normal Normal Normal Normal
male.
.51e1.24 mg/dl; Hb, 12.0e17.5 g/dl; C3, 0.8e1.8 g/L; C4, 0.1e0.4 g/L.
